The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. OppFi shares have added about 30.4% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for OppFi? OppFi Inc. (OPFI) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.29 per share a year ago. The ...

Core Viewpoint - Ceragon Networks reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, but down from $0.11 per share a year ago [1] - The company posted revenues of $82.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 8.01% and down from $96.09 million year-over-year [2] Financial Performance - Ceragon has surpassed consensus EPS estimates two times over the last four quarters [2] - The company has topped consensus revenue estimates three times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $101.25 million, and for the current fiscal year, it is $0.25 on revenues of $389.1 million [7] Stock Performance - Ceragon shares have declined approximately 51.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Outlook - The Wireless Non-US industry, to which Ceragon belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Ceragon's stock performance [5]

Core Viewpoint - CDW reported quarterly earnings of $2.6 per share, exceeding the Zacks Consensus Estimate of $2.49 per share, and showing an increase from $2.5 per share a year ago, indicating a positive earnings surprise of +4.42% [1] Financial Performance - CDW's revenues for the quarter ended June 2025 were $5.98 billion, surpassing the Zacks Consensus Estimate by 8.51%, and up from $5.42 billion year-over-year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates three times and topped revenue estimates three times [2] Stock Performance and Outlook - CDW shares have declined approximately 5.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $2.62 for the coming quarter and $9.73 for the current fiscal year [7] Industry Context - The Computers - IT Services industry, to which CDW belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that monitoring these revisions can be beneficial for investors [5]

Core Viewpoint - LivaNova reported quarterly earnings of $1.05 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, and showing an increase from $0.93 per share a year ago, indicating a strong earnings surprise of +25.00% [1][2] Financial Performance - The company achieved revenues of $352.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.56% and up from $318.6 million year-over-year [2] - Over the last four quarters, LivaNova has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - LivaNova shares have declined approximately 8% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.91 on revenues of $331.4 million, and for the current fiscal year, it is $3.65 on revenues of $1.32 billion [7] - The outlook for the Medical - Instruments industry, where LivaNova operates, is currently in the bottom 41% of Zacks industries, which may impact stock performance [8]

分组1 - MDxHealth SA reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, but an improvement from a loss of $0.31 per share a year ago, indicating a surprise of -15.38% [1] - The company posted revenues of $26.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02% and showing an increase from $22.16 million in the same quarter last year [2] - MDxHealth SA shares have increased by approximately 4.2% since the beginning of the year, while the S&P 500 has gained 7.6%, indicating underperformance relative to the broader market [3] 分组2 - The earnings outlook for MDxHealth SA is uncertain, with current consensus EPS estimates of -$0.11 for the coming quarter and -$0.52 for the current fiscal year, alongside expected revenues of $27.8 million and $108.5 million respectively [7] - The Zacks Industry Rank places the Medical Info Systems sector in the top 29% of over 250 Zacks industries, suggesting that companies in the top half of the rankings tend to outperform those in the bottom half by more than 2 to 1 [8] - The estimate revisions trend for MDxHealth SA was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6]

Group 1 - American Well Corporation (AMWL) reported a quarterly loss of $1.24 per share, which was better than the Zacks Consensus Estimate of a loss of $1.84, and an improvement from a loss of $3.36 per share a year ago, resulting in an earnings surprise of +32.61% [1] - The company posted revenues of $70.9 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 11.42%, and showing an increase from year-ago revenues of $62.79 million [2] - American Well has surpassed consensus EPS estimates four times over the last four quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has underperformed the market, losing about 2.9% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.98 on revenues of $63.11 million, and for the current fiscal year, it is -$6.91 on revenues of $255.84 million [7] - The Medical Info Systems industry, to which American Well belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Group 1: Earnings Performance - Hackett Group reported quarterly earnings of $0.38 per share, matching the Zacks Consensus Estimate, but down from $0.39 per share a year ago [1] - The company posted revenues of $77.63 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.30% and up from $75.9 million year-over-year [2] - Over the last four quarters, Hackett Group has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Group 2: Stock Performance and Outlook - Hackett Group shares have declined approximately 24.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.43 for the coming quarter and $1.64 for the current fiscal year [4][7] - The estimate revisions trend for Hackett Group was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Consulting Services industry, to which Hackett Group belongs, is currently ranked in the top 12% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Kemper reported quarterly earnings of $1.3 per share, missing the Zacks Consensus Estimate of $1.52 per share, and down from $1.42 per share a year ago, representing an earnings surprise of -14.47% [1] - The company posted revenues of $1.23 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.34%, and up from $1.13 billion year-over-year [2] - Over the last four quarters, Kemper has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - Kemper shares have lost about 8.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.57 on $1.26 billion in revenues, and for the current fiscal year, it is $6.34 on $4.98 billion in revenues [7] Industry Context - The Zacks Industry Rank for Insurance - Multi line is currently in the top 38% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5][6]

Financial Performance - Evolus, Inc. reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -166.67% [1] - The company posted revenues of $69.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 16.33%, compared to year-ago revenues of $66.91 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Evolus shares have declined approximately 17.5% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for Evolus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $86.76 million, and -$0.11 on revenues of $350.01 million for the current fiscal year [7] - The outlook for the Medical - Products industry, to which Evolus belongs, is currently in the bottom 38% of over 250 Zacks industries, which may impact the stock's performance [8]

Group 1: Earnings Performance - California Resources Corporation (CRC) reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $0.91 per share, and up from $0.6 per share a year ago, representing an earnings surprise of +20.88% [1] - The company posted revenues of $978 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 21.84%, compared to year-ago revenues of $514 million [2] - Over the last four quarters, California Resources has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - California Resources shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the coming quarter is $1.06 on revenues of $845.76 million, and for the current fiscal year, it is $3.71 on revenues of $3.32 billion [7] - The company's earnings outlook and estimate revisions will be crucial for future stock performance, with a current Zacks Rank of 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Oil and Gas - Exploration and Production - United States industry is currently in the bottom 31% of over 250 Zacks industries, which may impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5]